{"id":654,"date":"2020-08-11T14:11:05","date_gmt":"2020-08-11T06:11:05","guid":{"rendered":"http:\/\/web.csh.org.tw\/web\/cshmagazine\/?p=654"},"modified":"2020-08-11T14:11:06","modified_gmt":"2020-08-11T06:11:06","slug":"%e5%be%a9%e7%99%bc%e6%88%96%e9%a0%91%e5%9b%ba%e5%9e%8b%e6%85%a2%e6%80%a7%e6%b7%8b%e5%b7%b4%e7%90%83%e7%99%bd%e8%a1%80%e7%97%85%e7%9a%84%e6%96%b0%e6%b2%bb%e7%99%82","status":"publish","type":"post","link":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/?p=654","title":{"rendered":"\u5fa9\u767c\u6216\u9811\u56fa\u578b\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c5\u7684\u65b0\u6cbb\u7642"},"content":{"rendered":"\n<p style=\"text-align:right\">\u6587\/\u8840\u6db2\u816b\u7624\u79d1 <strong>\u9ec3\u5049\u4fee<\/strong> \u4e3b\u6cbb\u91ab\u5e2b<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"alignright is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/web.csh.org.tw\/web\/cshmagazine\/wp-content\/uploads\/2020\/08\/Y1379-767x1024.jpg\" alt=\"\" class=\"wp-image-638\" width=\"192\" height=\"256\"\/><figcaption>\u8840\u6db2\u816b\u7624\u79d1 \u9ec3\u5049\u4fee\u91ab\u5e2b<\/figcaption><\/figure><\/div>\n\n\n\n<p>\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u7403(Chronic\nlymphocytic leukemia, CLL)\u7684\u767c\u751f\u7387\u5728\u6b50\u7f8e\u570b\u5bb6\u9060\u9ad8\u65bc\u65b0\u52a0\u5761\u3001\u53f0\u7063\u3001\u4e2d\u570b\u3001\u65e5\u672c\u3001\u97d3\u570b\u7b49\u4e9e\u6d32\u570b\u5bb6\uff0c\u800c\u53f0\u7063\u7684\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u7403\u76db\u884c\u7387\u8fd1\u5e74\u6709\u4e0a\u5347\u7684\u8da8\u52e2\uff0c\u96d6\u7136\u662f\u9032\u5c55\u6bd4\u8f03\u6162\u7684\u767d\u8840\u75c5\uff0c\u4f46\u4f9d\u64da\u6fb3\u6d32\u7684\u7d71\u8a08\uff0c\u5f9e\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u7403\u78ba\u5b9a\u8a3a\u65b7\u5f8c5\u5e74\u7684\u6b7b\u4ea1\u7387\u70ba18%\uff0c\u8207\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u76845\u5e74\u6b7b\u4ea1\u738724%\u63a5\u8fd1\u3002<\/p>\n\n\n\n<p>\u00a0\u5c0d\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c5\u7684\u75c5\u4eba\u82e5\u53ea\u6709\u6dcb\u5df4\u7403\u589e\u52a0\u4e14\u7121\u75c7\u72c0\u8005\uff0c\u53ef\u4ee5\u5b9a\u671f\u8ffd\u8e64\u6aa2\u67e5\uff0c\u82e5\u767d\u8840\u7403\u6578\u6301\u7e8c\u589e\u52a0\uff0c\u75c5\u4eba\u7522\u751f\u8ca7\u8840\u3001\u813e\u816b\u5927\u3001\u6dcb\u5df4\u817a\u816b\u5927\u6216\u8840\u5c0f\u677f\u6578\u964d\u4f4e\uff0c\u53ef\u63a1\u7528\u53e3\u670d\u5316\u7642\u85e5\u7269\uff1a\u7624\u514b\u5be7(leukeran)\u53ca\u666e\u5229\u591a\u5be7(prednisolone)\u6cbb\u7642\uff0c\u4e5f\u53ef\u4ee5\u4f7f\u7528\u5316\u7642\u85e5\uff1a\u798f\u9054\u6a02\u975c\u8108\u51cd\u6676\u6ce8\u5c04\u5291(Fludarabine)\u3001\u764c\u5f97\u661f\u6ce8\u5c04\u5291(cyclophosphamide)\u53ca\u6a19\u9776\u85e5-\u83ab\u9808\u7624\u6ce8\u5c04\u5291(rituximab)\uff0c\u9019\u4e09\u7a2e\u85e5\u7269\u7684\u7d44\u5408\u7a31\u70baFCR\u975c\u8108\u6ce8\u5c04\u6cbb\u7642\uff0c\u6216\u63a1\u7528\u5316\u7642\u85e5\uff1a\u666e\u764c\u6c70(bendamustin)\u53ca\u83ab\u9808\u7624\u6ce8\u5c04\u5291(rituximab)\uff0c\u9019\u5169\u7a2e\u85e5\u7269\u7d44\u5408\u7a31\u4e4b\u70baBR\u975c\u8108\u6ce8\u5c04\u6cbb\u7642\u3002<\/p>\n\n\n\n<p>\u82e5\u75c5\u4eba\u75be\u75c5\u5fa9\u767c\u6216\u5c0d\u7b2c\u4e00\u7dda\u5316\u7642\u6548\u679c\u4e0d\u4f73\u6642\uff0c\u4f7f\u7528\u5316\u7642\u85e5\u7269FCR\u6216BR\u50c5\u80fd\u63d0\u4f9b14\u523030\u500b\u6708\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f(progression free survival, PFS)\uff0c\u82e5\u4f7f\u7528\u53e3\u670d\u6a19\u9776\u85e5-\u5104\u73c2\u81a0\u56ca(ibrutinib)\u6cbb\u76423\u5e74PFS\u7387\u70ba59%\uff0c\u800cMURANO\u8a66\u9a57\u7d50\u679c\u986f\u793a\u4ee5\u6a19\u9776\u85e5-\u552f\u53ef\u4f86\u819c\u8863\u9320\u52a0\u4e0a\u83ab\u9808\u7624venetoclax+rituximab(VenR)\u76843\u5e74PFS\u53ef\u905470%\u3002\u7531\u65bcVenR\u5c0d\u9ad8\u98a8\u96aa\u9810\u5f8c\u8f03\u5dee\u7684del(17P)\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c5\u7684\u75c5\u4eba\u4ecd\u6709\u8f03\u597d\u7684\u7642\u6548\uff0c\u885b\u751f\u798f\u5229\u90e8\u4e2d\u592e\u5065\u5eb7\u4fdd\u96aa\u7f72\u5df2\u7d66\u4ed8\u5728\u7b2c\u4e8c\u7dda\u4e8b\u524d\u7533\u8acb\u7d66\u4ed8\u4f7f\u7528\u3002<\/p>\n\n\n\n<p>\u570b\u5167\u6709\u7528\u552f\u53ef\u4f86\u819c\u8863\u9320(venetoclax)\u55ae\u65b9\u6cbb\u7642\u66fe\u63a5\u53d7BR\u5f8c\u5fa9\u767c\u7684\u75c5\u4f8b\u53ca\u4ee5\u5104\u73c2\u81a0\u56ca(ibrutinib)\u6cbb\u7642\u53ea\u5f97\u5230\u90e8\u5206\u53cd\u61c9\u75c5\u4f8b\uff0c\u6cbb\u7642\u5f8c\u90fd\u7372\u5f97\u5b8c\u5168\u7de9\u89e3\u3002<\/p>\n\n\n\n<p>\u672c\u9662\u4e00\u4f4d59\u6b72\u7684\u5973\u6027\u75c5\u60a3\uff0c\u65bc101\u5e74\u8a3a\u65b7\u51faCLL\u5f8c\u53ea\u6709\u5b9a\u671f\u8ffd\u8e64\u6aa2\u67e5\uff0c\u4e26\u672a\u63a5\u53d7\u4efb\u4f55\u6cbb\u7642\uff0c\u76f4\u5230104\u5e74\u958b\u59cb\u813e\u81df\u9010\u6f38\u816b\u5927\uff0c\u6709\u8f15\u5ea6\u8ca7\u8840\u53ca\u8840\u5c0f\u677f\u6578\u964d\u4f4e\uff0c107\u5e74\u767d\u8840\u7403\u657881740\/ul\u3001\u8840\u8272\u7d209.9g\/dl\u3001\u8840\u5c0f\u677f\u657899000\/ul\uff0c\u958b\u59cb\u6bcf\u65e5\u670d\u7528\u7624\u514b\u5be7(leukeran) 2mg\u5f8c\u767d\u8840\u7403\u6578\u964d\u4f4e\uff0c\u8ca7\u8840\u7372\u5f97\u6539\u5584\uff0c\u4f46\u8840\u5c0f\u677f\u6578\u76ee\u4ecd\u504f\u4f4e\u3002<\/p>\n\n\n\n<p>108\u5e74\u75c5\u4eba\u670d\u7528\u7624\u514b\u5be7(leukeran)\u6cbb\u7642\u5f8c\u767d\u8840\u7403\u6578\u53ca\u6dcb\u5df4\u7403\u6578\u76ee\u4ecd\u672a\u7372\u6539\u5584\uff0c\u813e\u81df\u66f4\u660e\u986f\u816b\u5927\uff0c\u65bc109\u5e741\u6708\u5f8c\u56e0\u8840\u5c0f\u677f\u4f4e\u53ca\u51fa\u73fe\u6d41\u9f3b\u8840\uff0c\u5e38\u9700\u5728\u9580\u8a3a\u8f38\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\u6cbb\u7642\uff0c\u8840\u6db2\u57fa\u56e0\u6aa2\u6e2c\u6c92\u670917P\u8b8a\u7570\uff0c\u56e0\u6b64\u65bc109\u5e743\u670817\u65e5\u958b\u59cb\u81ea\u8cbb\u4f7f\u7528\u4f4e\u5291\u91cf\u552f\u53ef\u4f86\u819c\u8863\u9320(venetoclax)\uff0c\u4ee5\u907f\u514d\u7522\u751f\u816b\u7624\u74e6\u89e3\u75c7\u5019\u7fa4\uff0c\u6240\u5e78\u75c5\u4eba\u7121\u526f\u4f5c\u7528\uff0c\u767d\u8840\u7403\u6578\u9010\u6f38\u753148600\/ul\u964d\u81f36050\/ul\uff0c\u6dcb\u5df4\u7403\u753191%\u964d\u81f324%\uff0c\u8840\u8272\u7d20\u5347\u81f313.5g\/dl \u3002<\/p>\n\n\n\n<p>\u76ee\u524d\u75c5\u4eba\u6301\u7e8c\u63a5\u53d7\u53e3\u670d\u6bcf\u65e5\u552f\u53ef\u4f86\u819c\u8863\u9320(venetoclax)\n400\u6beb\u514b\u6cbb\u7642\u5df2\u4e09\u500b\u6708\uff0c\u8840\u5c0f\u677f\u6578\u96d6\u4f4e\uff0c\u4f46\u5df2\u4e0d\u9700\u8f38\u8840\u5c0f\u677f\u6cbb\u7642\uff0c\u813e\u81df\u4e5f\u5df2\u6062\u5fa9\u6b63\u5e38\u5927\u5c0f\u3002<\/p>\n\n\n\n<p>\u7531\u4e0a\u8ff0\u6cbb\u7642\u7d93\u9a57\uff0c\u55ae\u4e00\u8655\u65b9\u552f\u53ef\u4f86\u819c\u8863\u9320(venetoclax)\u6cbb\u7642\u5fa9\u767c\u6216\u60e1\u5316\u7684CLL\u975e\u5e38\u6709\u6548\uff0c\u75c5\u60a3\u5c0d\u85e5\u7269\u8010\u53d7\u6027\u4e5f\u9ad8\u3002<\/p>\n\n\n\n<p>\u9019\u4e9b\u90fd\u662f\u672c\u9662\u8840\u6db2\u816b\u7624\u79d1\u6cbb\u7642\u5fa9\u767c\u6216\u9811\u56fa\u578b\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c5\u7684\u6210\u679c\uff0c\u76f8\u4fe1\u9019\u9805\u65b0\u6cbb\u7642\u6cd5\uff0c\u5c0d\u65bcCLL\u75c5\u4eba\u662f\u4e00\u5247\u597d\u6d88\u606f\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u6587\/\u8840\u6db2\u816b\u7624\u79d1 \u9ec3\u5049\u4fee \u4e3b\u6cbb\u91ab\u5e2b \u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u7403(Chronic lymphocytic leukemia, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"class_list":["post-654","post","type-post","status-publish","format-standard","hentry","category-19"],"_links":{"self":[{"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=\/wp\/v2\/posts\/654"}],"collection":[{"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=654"}],"version-history":[{"count":1,"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=\/wp\/v2\/posts\/654\/revisions"}],"predecessor-version":[{"id":655,"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=\/wp\/v2\/posts\/654\/revisions\/655"}],"wp:attachment":[{"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/cshmagazine\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}